I am interested in what the hon. Lady says about medicines and vaccines. Yes, the mutual recognition principle is extremely helpful in allowing British companies to work with others across Europe and a single market for medicines, but I understand there are issues that make it more difficult for those same pharmaceutical developers to share data with, say, American counterparts. Under the comprehensive economic and trade agreement, which as I have said before in the House is not perfect for the UK, there are potential benefits to mutual recognition not only with Europe but with other countries. Does she not agree that we want both types of agreement if possible?
Exiting the European Union and Global Trade
Proceeding contribution from
Vicky Ford
(Conservative)
in the House of Commons on Thursday, 6 July 2017.
It occurred during Debate on Exiting the European Union and Global Trade.
Type
Proceeding contribution
Reference
626 c1393 
Session
2017-19
Chamber / Committee
House of Commons chamber
Subjects
Librarians' tools
Timestamp
2022-08-29 17:14:04 +0100
URI
http://hansard.intranet.data.parliament.uk/Commons/2017-07-06/17070636000016
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2017-07-06/17070636000016
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2017-07-06/17070636000016